Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30148899 | 0.94 | KDM1A (0.33) | HSD11B1TSHR | |
| SCHEMBL5818626 | 0.83 | LMNA (0.33) | HTTLMNATSHR | |
| SCHEMBL23098591 | 0.71 | CA1 (0.33) | LMNATSHR | |
| SCHEMBL15684079 | 0.67 | GRM2 (0.42) | HTTLMNATSHR | |
| SCHEMBL30170309 | 0.66 | KDM1A (0.54) | — | |
| SCHEMBL19030669 | 0.66 | KDM1A (0.54) | — | |
| SCHEMBL30194273 | 0.66 | KDM1A (0.54) | — | |
| SCHEMBL19041432 | 0.66 | KDM1A (0.54) | — | |
| SCHEMBL30194202 | 0.66 | KDM1A (0.54) | — | |
| SCHEMBL19041299 | 0.66 | KDM1A (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115521325-A | Boronic acid derivatives | 首药控股(北京)股份有限公司 | 2022-12-27 | — | — | CN | disclosed |
| EP-1656141-B1 | TREATMENT FOR ALZHEIMER S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME (GB) | 2010-04-14 | — | — | EP | disclosed |
| EP-1656141-B1 | TREATMENT FOR ALZHEIMER S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME (GB) | 2010-04-14 | — | — | EP | disclosed |
| US-20080153817-A1 | Treatment for Alzheimer's Disease and Related Conditions | MERCK SHARP & DOHME LTD. (GB) | 2008-06-26 | — | — | US | disclosed |
| US-20080153817-A1 | Treatment for Alzheimer's Disease and Related Conditions | MERCK SHARP & DOHME LTD. (GB) | 2008-06-26 | — | — | US | disclosed |
| US-20080153817-A1 | Treatment for Alzheimer's Disease and Related Conditions | MERCK SHARP & DOHME LTD. (GB) | 2008-06-26 | — | — | US | disclosed |
| WO-2005013985-A1 | TREATMENT FOR ALZHEIMER'S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153817-A1 | Treatment for Alzheimer's Disease and Related Conditions | PSEN1, PSEN2, APP | HTT 43/4885HSD11B1 227/4885HDAC4 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.